Elderly patients (aged ≥65 years) with acute myeloid leukaemia have poor outcomes and no effective standard-of-care therapy exists. Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest and typically short-lived. The oral anti-apoptotic B-cell lymphoma 2 protein inhibitor, venetoclax, has shown promising single-agent activity in patients with relapsed or refractory acute myeloid leukaemia and preclinical data suggested synergy between hypomethylating agents and venetoclax, which led to this combination phase 1b study.

中文翻译：

---

Venetoclax与地西他滨或阿扎胞苷在先前未经治疗的急性髓性白血病的老年患者中的安全性和初步疗效：一项非随机，开放标签的1b期研究。

患有急性髓细胞性白血病的老年患者（≥65岁）的预后较差，并且不存在有效的护理标准治疗方法。用次甲基化剂如阿扎胞苷和地西他滨治疗是常见的，但是反应中等，并且通常是短暂的。口服抗凋亡B细胞淋巴瘤2蛋白抑制剂Venetoclax在复发或难治性急性髓细胞白血病患者中显示出令人鼓舞的单药活性，并且临床前数据表明低甲基化剂与Venetoclax之间存在协同作用，从而导致了该组合1b期研究。